Literature DB >> 10882040

Effects of JTV-519, a novel anti-ischaemic drug, on the delayed rectifier K+ current in guinea-pig ventricular myocytes.

K Kiriyama1, T Kiyosue, J C Wang, K Dohi, M Arita.   

Abstract

We studied the effects of a newly synthesized anti-ischaemic agent, 4-[3-(4-benzylpiperidin-1-yl) propionyl]-7-methoxy-2, 3, 4, 5-tetrahydro-1, 4-benzothiazepine monohydrochloride (JTV-519) on the delayed rectifier potassium current (IK), using guinea-pig ventricular myocytes and whole-cell voltage-clamp techniques, under blockade of the L-type calcium current (ICa,L) by D600 (1 microM) or nitrendipine (5 microM). The IK in guinea-pig ventricular cells consists of two different components; the rapidly activating, E4031-sensitive component (IKr) and the slowly activating E4031-resistant component (IKs). Under steady-state conditions, JTV-519 (1 and 5 microM) did not change the amplitude of IKs remaining after blockade of IKr with 5 microM E4031. The effect of JTV-519 on IKr was assessed using short (50 ms) pulses which evoked a tail current that was sensitive to E4031 but not to chromanol 293B, a specific blocker of IKs. JTV-519 suppressed the IKr with a half-maximal inhibitory concentration of 1.2 microM. Selective inhibition of IKr by this agent was confirmed by using the "envelope of tails" test. These results suggest that the blockade of IKr may underlie the prolongation of action potential duration in ventricular muscle and QT-intervals alleged to occur in animal as well as human hearts.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10882040     DOI: 10.1007/s002100000230

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  14 in total

1.  Designing calcium release channel inhibitors with enhanced electron donor properties: stabilizing the closed state of ryanodine receptor type 1.

Authors:  Yanping Ye; Daniel Yaeger; Laura J Owen; Jorge O Escobedo; Jialu Wang; Jeffrey D Singer; Robert M Strongin; Jonathan J Abramson
Journal:  Mol Pharmacol       Date:  2011-10-11       Impact factor: 4.436

2.  The effect of K201 on isolated working rabbit heart mechanical function during pharmacologically induced Ca2+ overload.

Authors:  A Kelly; E B Elliott; R Matsuda; N Kaneko; G L Smith; C M Loughrey
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

3.  Treatment of catecholaminergic polymorphic ventricular tachycardia in mice using novel RyR2-modifying drugs.

Authors:  Na Li; Qiongling Wang; Martha Sibrian-Vazquez; Robert C Klipp; Julia O Reynolds; Tarah A Word; Larry Scott; Guy Salama; Robert M Strongin; Jonathan J Abramson; Xander H T Wehrens
Journal:  Int J Cardiol       Date:  2016-10-29       Impact factor: 4.164

4.  Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle function in heart failure.

Authors:  Xander H T Wehrens; Stephan E Lehnart; Steven Reiken; Roel van der Nagel; Raymond Morales; Jie Sun; Zhenzhuang Cheng; Shi-Xiang Deng; Leon J de Windt; Donald W Landry; Andrew R Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-22       Impact factor: 11.205

5.  2APB- and JTV519(K201)-sensitive micro Ca2+ waves in arrhythmogenic Purkinje cells that survive in infarcted canine heart.

Authors:  Penelope A Boyden; Wen Dun; Chirag Barbhaiya; Henk E D J Ter Keurs
Journal:  Heart Rhythm       Date:  2004-07       Impact factor: 6.343

6.  Bradycardia alters Ca(2+) dynamics enhancing dispersion of repolarization and arrhythmia risk.

Authors:  Jong J Kim; Jan Němec; Rita Papp; Robert Strongin; Jonathan J Abramson; Guy Salama
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-01-11       Impact factor: 4.733

Review 7.  Calcium cycling proteins and heart failure: mechanisms and therapeutics.

Authors:  Andrew R Marks
Journal:  J Clin Invest       Date:  2013-01-02       Impact factor: 14.808

Review 8.  Dysfunctional ryanodine receptors in the heart: new insights into complex cardiovascular diseases.

Authors:  Steven O Marx; Andrew R Marks
Journal:  J Mol Cell Cardiol       Date:  2013-03-16       Impact factor: 5.000

Review 9.  Pharmacological characteristics and clinical applications of K201.

Authors:  Noboru Kaneko; Ryuko Matsuda; Yoshihito Hata; Ken Shimamoto
Journal:  Curr Clin Pharmacol       Date:  2009-05

10.  Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?

Authors:  U Deniz Dincer
Journal:  Diabetes Metab Syndr Obes       Date:  2012-04-05       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.